In the study of glioma (GBM), it was found that overexpression of SOX2 can significantly enhance the stem cell phenotype of GBM [95], while silencing the expression of SOX2 by RNAi technology can inhibit the proliferation of GBM stem cells and deactivate them [96, 97]. The gene discussed is SOX2; the disease is glioblastoma.